Roche's End Run Into the Cervical Cancer Screening Market

When Roche Molecular Systems Inc. (RMS, the molecular diagnostics division of Roche ), entered into an agreement last year with Digene Corp. to co-promote Digene's screening test for human papilloma virus [See Deal], it did so in contemplation of an eventual broader relationship with Digene. Indeed, the companies had already begun to explore the possibility of Roche acquiring Digene, which has a strong intellectual property portfolio of HPV markers and the only FDA-approved test for HPV—the cause of virtually all cervical cancer and a key women's health test. Adding HPV to its growing panel of molecular infectious disease tests was therefore an obvious goal for Roche.